influenza
b
virus
ibv
caus
annual
outbreak
respiratori
ill
human
increasingli
recogn
major
caus
influenzaassoci
morbid
mortal
studi
influenza
virus
requir
use
secondari
methodolog
identifi
virusinfect
cell
end
replicationcompet
influenza
virus
iav
express
easili
traceabl
fluoresc
protein
recent
develop
contrast
similar
approach
ibv
mostli
lack
report
describ
gener
character
replicationcompet
influenza
virus
express
fluoresc
mcherri
gfp
fuse
ctermin
viral
nonstructur
protein
fluorescentexpress
ibv
display
similar
growth
kinet
plaqu
phenotyp
wildtyp
ibv
fluoresc
protein
express
allow
easi
identif
virusinfect
cell
without
need
secondari
approach
monitor
viral
infect
fluorescentexpress
ibv
repres
ideal
approach
studi
biolog
ibv
excel
platform
rapid
identif
character
antivir
therapeut
neutral
antibodi
use
highthroughput
screen
approach
lastli
fluorescentexpress
ibv
combin
recent
describ
reporterexpress
iav
identif
novel
therapeut
combat
two
import
human
respiratori
pathogen
influenza
virus
belong
famili
orthomyxovirida
divid
type
b
c
pales
shaw
despit
use
vaccin
type
b
influenza
virus
iav
ibv
respect
infect
human
regularli
respons
yearli
season
epidem
associ
signific
public
health
econom
consequ
molinari
et
al
estim
year
thousand
peopl
worldwid
contract
influenza
develop
acut
respiratori
infect
signific
morbid
mortal
luckhaupt
et
al
molinari
et
al
thompson
et
al
iav
classifi
differ
subtyp
base
antigen
major
surfac
glycoprotein
hemagglutinin
ha
subtyp
neuraminidas
na
subtyp
pales
shaw
tong
et
al
tong
et
al
unlik
iav
ibv
divid
antigen
distinct
subtyp
although
sinc
two
lineag
diverg
ancestr
influenza
viru
strain
cocircul
human
popul
chen
holm
mcculler
et
al
current
iav
subtyp
ibv
circul
human
shaw
pales
tong
et
al
tong
et
al
iav
ibv
follow
rather
diffus
cyclic
epidem
pattern
base
preval
typic
everi
year
hite
et
al
li
et
al
lin
et
al
olson
et
al
ibv
epidem
tend
less
sever
iav
sever
aiv
adult
elderli
ohmit
monto
olson
et
al
thompson
et
al
van
vori
et
al
howev
ibv
infect
associ
excess
morbid
mortal
pediatr
popul
belsh
hite
et
al
li
et
al
olson
et
al
contrari
iav
broad
host
reservoir
mani
avian
mammalian
speci
ibv
mainli
restrict
human
wright
et
al
although
occasion
infect
seal
document
osterhau
et
al
vaccin
antivir
avail
combat
influenza
virus
baker
et
al
burnham
et
al
jackson
et
al
krammer
et
al
nguyen
et
al
seibert
et
al
histor
influenza
vaccin
contain
viral
antigen
correspond
preval
iav
well
one
lineag
influenza
type
b
victoria
yamagata
belsh
et
al
yang
recent
due
increas
cocircul
ibv
lineag
signific
antigen
diverg
advisori
committe
immun
practic
acip
recommend
influenza
vaccin
avail
quadrival
formul
grohskopf
et
al
sun
respect
antivir
four
class
fdaapprov
drug
use
influenza
infect
rimantadin
amantadin
target
viral
matrix
ion
channel
inhibit
viral
entri
hay
et
al
effect
protein
ibv
beigel
bray
zanamivir
oseltamivir
target
sialidas
activ
influenza
viru
na
inhibit
viru
releas
effect
iav
ibv
jackson
et
al
low
clinic
effect
na
inhibitor
ibv
children
emerg
drug
resist
variant
treatment
report
burnham
et
al
farruke
et
al
plasmidbas
revers
genet
gener
recombin
influenza
virus
fodor
et
al
neumann
et
al
significantli
contribut
better
understand
biolog
import
human
respiratori
pathogen
engelhardt
jackson
et
al
identif
character
antivir
baker
et
al
ozawa
kawaoka
robert
et
al
develop
altern
influenza
vaccin
baker
et
al
nogal
et
al
subbarao
katz
revers
genet
allow
gener
replicationcompet
iav
express
report
gene
novel
power
tool
track
viral
infect
without
requir
secondari
methodolog
detect
viralinfect
cell
eckert
et
al
fieg
langloi
fukuyama
et
al
kittel
et
al
manicassami
et
al
nogal
et
al
pan
et
al
perez
et
al
reuther
et
al
tran
et
al
contrast
similar
approach
implement
extend
ibv
describ
character
recombin
ibv
base
victoria
lineag
strain
fluoresc
protein
mcherri
gfp
fuse
ctermin
end
viral
nogal
et
al
fluorescentexpress
ibv
similar
growth
kinet
plaqu
phenotyp
respect
wildtyp
wt
counterpart
importantli
ibv
infect
easili
track
realtim
use
fluoresc
microscopi
conveni
quantifi
use
fluoresc
plate
reader
elimin
use
secondari
approach
monitor
ibv
infect
replicationcompet
fluorescentexpress
ibv
repres
promis
option
studi
biolog
ibv
excel
platform
easili
identifi
evalu
antivir
neutral
antibodi
nab
use
highthroughput
screen
ht
approach
current
need
combat
import
human
respiratori
pathogen
human
embryon
kidney
atcc
canin
madindarbi
canin
kidney
mdck
atcc
cell
grown
co
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
fb
psg
penicillin
unitsml
streptomycin
lglutamin
mm
nogal
et
al
engin
ibv
ns
segment
ctermin
fuse
fluoresc
mcherri
codonoptim
maxgfp
gfp
amaxa
recombin
ns
segment
synthes
de
novo
biomatik
appropri
restrict
site
subclon
ambisens
plasmid
pena
et
al
plasmid
name
contain
open
read
frame
orf
without
stop
codon
splice
acceptor
site
two
bsmbi
site
opposit
orient
follow
porcin
autoproteolyt
cleavag
site
atnfsllkqagdveenpgp
entir
sequenc
nuclear
export
protein
nep
nogal
et
al
mcherri
gfp
orf
amplifi
pcr
use
oligonucleotid
design
introduc
complementari
bsmbi
site
clone
gener
pdpnsmcherri
pdpnsgfp
plasmid
ibv
rescu
oligonucleotid
clone
mcherri
gfp
plasmid
avail
upon
request
plasmid
construct
confirm
sequenc
acgt
inc
ambisens
plasmid
use
rescu
wt
reporterexpress
b
previous
describ
baker
et
al
pena
et
al
briefli
cocultur
cell
plate
format
cellswel
cotransfect
suspens
eight
ambisens
pa
ha
np
na
wt
ns
nsmcherri
nsgfp
plasmid
clonal
wt
mcherryor
gfpexpress
ibv
select
plaqu
assay
viru
stock
propag
mdck
cell
co
atmospher
day
influenza
wt
mcherri
virus
previous
describ
nogal
et
al
infect
viru
stock
dilut
phosphat
buffer
salin
pb
supplement
bovin
albumin
ba
ps
pbsbap
viral
infect
cell
maintain
dmem
supplement
ba
psg
tosylsulfonyl
phenylalanyl
chloromethyl
keton
tpck
treat
trypsin
sigma
martinezsobrido
garciasastr
viru
titer
determin
standard
plaqu
assay
plaqu
form
unit
pfu
ml
mdck
cell
nogal
et
al
multicycl
viru
growth
kinet
perform
mdck
cell
plate
format
cellswel
infect
indic
virus
triplic
multipl
infect
moi
viru
titer
tissu
cultur
supernat
determin
immunofocu
assay
fluoresc
focusform
unit
ffuml
nogal
et
al
use
mous
monoclon
antibodi
mab
iav
oneil
et
al
ibv
abcam
np
fluorescein
isothiocyan
fitc
conjug
antimous
secondari
antibodi
dako
mean
valu
standard
deviat
sd
calcul
use
microsoft
excel
softwar
cell
extract
either
mock
virusinfect
moi
mdck
cell
plate
format
cellswel
lyse
h
postinfect
hpi
passiv
lysi
buffer
promega
separ
denatur
electrophoresi
previous
describ
nogal
et
al
membran
block
h
dri
skim
milk
pb
contain
tween
tpb
incub
overnight
indic
primari
monoclon
polyclon
pab
antibodi
ibv
np
mous
mab
abcam
mcherri
rabbit
pab
raybiotech
ibv
rabbit
pab
kindli
provid
dr
wolff
dauber
et
al
actin
mous
mab
sigma
bound
primari
antibodi
detect
horseradish
peroxidas
hrp
conjug
antimous
antirabbit
antibodi
gehealthcar
protein
detect
chemiluminesc
hyglo
dennvil
scientif
accord
manufactur
recommend
total
rna
mock
virusinfect
moi
mdck
cell
collect
hpi
purifi
use
trizol
reagent
invitrogen
accord
manufactur
specif
cdna
synthes
use
superscript
ii
revers
transcriptas
invitrogen
oligodt
primer
amplifi
total
mrna
mcherri
gapdh
specif
primer
ns
np
vrna
cdna
use
templat
semiquantit
pcr
primer
specif
ns
np
vrna
mcherri
canin
gapdh
mrna
avail
upon
request
confluent
monolay
mdck
cell
plate
format
cellswel
infect
wt
fluorescentexpress
ibv
h
room
temperatur
overlaid
agar
incub
three
day
postinfect
cell
fix
overnight
paraformaldehyd
pfa
overlay
remov
visual
mcherri
pb
ad
plate
imag
kodak
imag
station
pro
molecular
imag
system
carestream
health
inc
ny
nogal
et
al
kodak
molecular
imag
softwar
plate
permeabil
triton
pb
min
room
temperatur
prepar
immunostain
previous
describ
nogal
et
al
use
anti
ibv
np
mab
vector
kit
vectastain
abc
kit
dab
hrp
substrat
kit
vector
accord
manufactur
specif
mdck
cell
mockinfect
infect
moi
wt
fluorescentexpress
ibv
hpi
cell
fix
pfa
permeabil
triton
pb
min
room
temperatur
stain
perform
describ
previous
nogal
et
al
use
primari
ibv
np
mab
abcam
pab
dauber
et
al
antibodi
fitcconjug
antimous
np
antirabbit
antibodi
dako
cell
nucleu
stain
dapi
research
organ
imag
captur
use
fluoresc
microscop
nikon
eclips
magnif
pictur
process
use
adob
photoshop
softwar
viru
neutral
assay
perform
wt
mcherri
ibv
iav
previous
describ
nogal
et
al
briefli
goat
pab
influenza
bhong
bei
resourc
respect
heat
inactiv
min
serial
dilut
pb
use
plate
start
dilut
five
hundr
ffu
viru
ad
antibodi
dilut
incub
h
room
temperatur
mdck
cell
plate
format
cellswel
triplic
infect
antibodi
viru
mixtur
incub
h
wt
mcherri
iav
ibv
viru
neutral
determin
hemagglutin
inhibit
hi
assay
use
tissu
cultur
supernat
infect
cell
turkey
red
blood
cell
min
ice
guo
et
al
fluorescencebas
microneutr
assay
cell
wash
pb
prior
red
fluoresc
imag
use
fluoresc
microscopi
quantif
use
fluoresc
plate
reader
becton
dickenson
fluoresc
valu
mcherri
virusinfect
cell
absenc
antibodi
ab
use
calcul
viral
infect
cell
absenc
viral
infect
viru
use
calcul
fluoresc
background
triplic
well
use
calcul
mean
sd
neutral
inhibitori
concentr
ic
determin
sigmoid
dose
respons
curv
graphpad
prism
antiviralmedi
inhibit
wt
mcherri
ibv
iav
evalu
previous
describ
nogal
et
al
briefli
confluent
mdck
cell
cell
plate
format
triplic
infect
indic
virus
moi
h
infect
room
temperatur
infecti
media
supplement
serial
dilut
start
concentr
ribavirin
sidwel
et
al
amantadin
sigma
hpi
viru
titer
tissu
cultur
supernat
determin
ffu
nogal
et
al
determin
antivir
activ
mcherri
virus
confluent
mdck
cell
plate
format
cellswel
triplic
infect
moi
treat
indic
compound
previous
describ
nogal
et
al
hpi
cell
wash
pb
prior
red
fluoresc
imag
use
fluoresc
microscopi
quantif
use
fluoresc
plate
reader
becton
dickenson
fluoresc
valu
mcherri
virusinfect
cell
absenc
drug
drug
use
calcul
viral
infect
cell
absenc
viral
infect
viru
use
calcul
fluoresc
background
triplic
well
use
calcul
mean
sd
neutral
inhibitori
concentr
ic
determin
sigmoid
dose
respons
curv
graphpad
prism
order
engin
replicationcompet
ibv
express
mcherri
segment
encod
nep
open
read
frame
modifi
follow
similar
previous
describ
approach
manicassami
et
al
nogal
et
al
briefli
modifi
ibv
ns
segment
contain
two
bsmbi
restrict
site
opposit
orient
synthes
de
novo
introduc
mcherri
frame
sequenc
ns
segment
altern
splice
encod
nep
fig
two
silent
mutat
splice
acceptor
site
introduc
avoid
splice
hale
et
al
koch
et
al
manicassami
et
al
nogal
et
al
produc
nep
porcin
autoproteolyt
cleavag
site
insert
nep
order
viral
protein
translat
individu
fig
manicassami
et
al
manicassami
et
al
importantli
produc
full
length
nep
nep
ntermin
overlap
first
amino
acid
duplic
downstream
site
manicassami
et
al
nogal
et
al
mcherri
sequenc
clone
modifi
ns
segment
use
bsmbi
restrict
site
use
influenza
plasmidbas
revers
genet
baker
et
al
pena
et
al
gener
recombin
ibv
express
mcherri
ibvmcherri
fuse
cterminu
ident
ibvmcherri
first
confirm
rtpcr
fig
total
rna
extract
mock
ibv
wt
ibvmcherri
infect
moi
cell
hpi
expect
band
size
approxim
nt
observ
correspond
wt
mcherri
ns
vrna
segment
respect
fig
primer
specif
mcherri
amplifi
band
expect
size
nt
ibvmcherri
infect
cell
fig
control
viral
infect
cellular
transcript
viral
np
vrna
gapdh
mrna
level
respect
also
assess
fig
next
evalu
protein
express
level
western
blot
fig
total
cell
extract
either
mock
ibv
wt
ibvmcherri
infect
moi
mdck
cell
examin
hpi
use
antibodi
specif
mcherri
np
actin
load
control
western
blot
analysi
show
specif
band
protein
antibodi
fig
cell
extract
ibvmcherri
infect
cell
observ
addit
band
lower
molecular
size
might
repres
degrad
product
western
blot
analysi
mcherri
antibodi
detect
specif
band
cell
extract
ibvmcherri
infect
cell
fig
notabl
level
np
similar
wt
mcherri
ibvinfect
cell
fig
assess
whether
ibvmcherri
could
directli
visual
use
evalu
ibv
infect
confluent
monolay
mdck
cell
mock
infect
infect
moi
wt
mcherri
ibv
examin
fluoresc
mcherri
indirect
immunofluoresc
microscopi
use
specif
antibodi
ibv
np
fig
fig
hpi
subcellular
nuclear
local
ibv
np
similar
wt
mcherri
infect
cell
fig
likewis
ibv
similarli
distribut
wt
mcherri
infect
mdck
cell
fig
importantli
ibvmcherri
infect
cell
fluoresc
upon
direct
examin
fluoresc
microscop
use
red
filter
fig
altogeth
data
demonstr
mdck
cell
infect
ibvmcherri
express
high
level
mcherri
use
valid
surrog
monitor
ibv
infect
without
need
secondari
approach
detect
viral
infect
viru
kinet
wt
mcherri
ibv
next
examin
tissu
cultur
examin
multicycl
growth
properti
fig
plaqu
format
fig
viru
growth
kinet
confluent
monolay
mdck
cell
infect
moi
ibv
wt
ibvmcherri
presenc
viru
tissu
cultur
supernat
quantifi
differ
hpi
fig
recombin
mcherryexpress
ibv
replic
similar
level
ibv
wt
reach
maximum
titer
hpi
thu
introduct
mcherri
significantli
affect
ibv
growth
kinet
viral
replic
fig
evalu
plaqu
phenotyp
wt
mcherri
ibv
mdck
cell
size
infect
viral
foci
produc
ibvmcherri
similar
produc
ibv
wt
fig
importantli
plaqu
detect
use
antinp
ibv
mab
express
mcherri
fig
white
arrow
indic
infecti
recombin
ibv
express
mcherri
expect
ibvmcherri
form
fluoresc
plaqu
direct
fluoresc
visual
nab
influenza
viru
import
evalu
protect
efficaci
vaccin
approach
baker
et
al
couch
et
al
cox
brokstad
hancock
et
al
howev
except
ha
inhibit
hi
assay
approach
assess
antibodymedi
viru
neutral
usual
requir
secondari
method
detect
presenc
viru
cell
stain
immunofluoresc
assay
elisa
bauman
et
al
webster
et
al
limit
sidestep
use
recombin
influenza
virus
harbor
easili
traceabl
fluoresc
protein
whose
express
may
directli
monitor
nogal
et
al
shaner
et
al
demonstr
mcherryexpress
ibv
use
evalu
nab
respons
confluent
monolay
mdck
cell
infect
mcherryexpress
ibv
iav
previous
incub
haspecif
nab
ibv
baker
et
al
iav
couch
et
al
visual
fluoresc
express
use
fluoresc
microscopi
fig
quantifi
use
fluoresc
plate
reader
fig
e
respect
expect
ibvmcherri
specif
neutral
fig
turn
iavmcherri
exclus
neutral
fig
use
convent
viru
neutral
vn
assay
evalu
neutral
wt
mcherryexpress
virus
influenza
typespecif
antibodi
result
show
compar
level
neutral
wt
mcherri
virus
tabl
moreov
vn
data
correl
previous
observ
fluoresc
approach
percentag
inhibit
calcul
use
sigmoid
dose
respons
fig
f
tabl
altogeth
result
demonstr
ibvmcherri
use
evalu
nab
respons
fluorescencebas
microneutr
assay
recent
show
iav
mcherri
nogal
et
al
sinc
express
viralencod
mcherri
depend
ibv
infect
mcherri
use
valid
surrog
ibv
infect
demonstr
ibvmcherri
use
identif
antivir
examin
abil
ribavirin
cheung
et
al
nguyen
et
al
nguyen
et
al
nogal
et
al
amantadin
nguyen
et
al
nguyen
et
al
inhibit
mcherryexpress
iav
ibv
fig
ribavirin
nucleosid
analog
shown
effici
ibv
iav
infect
beigel
bray
contrast
amantadin
inhibitor
specif
target
protein
iav
antivir
activ
ibv
oxford
et
al
mdck
cell
cultur
plate
infect
mcherryexpress
ibv
fig
b
iav
fig
e
infect
cell
incub
medium
contain
serial
dilut
start
concentr
ribavirin
amantadin
infect
mdck
cell
lack
antivir
compound
use
intern
control
hpi
mcherri
express
determin
via
fluoresc
microscopi
fig
quantifi
use
fluoresc
plate
reader
fig
e
expect
mcherryexpress
ibv
iav
inhibit
ribavirin
dosedepend
manner
fig
howev
amantadin
show
dosedepend
antivir
activ
iavmcherri
ibvmcherri
fig
demonstr
mcherryexpress
virus
recapitul
similar
antivir
profil
wt
virus
evalu
antivir
activ
ribavirin
amantadin
tissu
cultur
supernat
mdck
cell
infect
wt
iav
ibv
viru
releas
tissu
cultur
supernat
determin
calcul
respect
ic
valu
use
classic
sigmoid
dose
respons
curv
tabl
regardless
drug
viru
use
ic
valu
similar
within
dilut
valu
tabl
consist
previous
report
literatur
nguyen
et
al
nguyen
et
al
sidwel
et
al
fluorescencebas
microneutr
assay
fig
f
tabl
import
note
iav
wt
mcherri
viru
backbon
higher
ic
valu
amantadin
iav
strain
due
mutat
channel
associ
drug
resist
nguyen
et
al
sidwel
et
al
overal
data
demonstr
ibvmcherri
use
valid
surrog
system
rapid
easi
identif
ibv
inhibitor
valid
use
molecular
approach
gener
reporterexpress
ibv
recombin
ibv
express
gfp
ibvgfp
gener
fig
ibvgfp
show
slightli
delay
kinet
fig
similar
plaqu
size
fig
ibv
wt
ibvmcherri
interestingli
ibvgfp
show
less
stabil
ibvmcherri
data
shown
resembl
similar
observ
iavgfp
fukuyama
et
al
manicassami
et
al
howev
abl
obtain
stabl
ibvgfp
clone
serial
plaqu
purif
mdck
cell
importantli
mdck
cell
infect
ibvgfp
express
high
level
gfp
fig
use
altern
report
combin
mcherryexpress
iav
andor
ibv
evalu
virusinfect
cell
nab
andor
antivir
data
demonstr
replicationcompet
ibv
express
differ
fluoresc
protein
feasibl
stabl
increas
arsen
type
recombin
virus
safe
amen
routin
viru
neutral
antivir
assay
recent
report
iav
fukuyama
et
al
manicassami
et
al
recombin
virus
express
fluoresc
protein
gener
monitor
viral
replic
includ
dna
eg
vaccinia
viru
diallo
et
al
dominguez
et
al
human
cytomegaloviru
marschal
et
al
doublestrand
eg
hiv
daeleman
et
al
positivestrand
eg
murin
hepat
viru
freeman
et
al
negativestrand
segment
eg
arenavirus
ortizriano
et
al
nonseg
eg
newcastl
diseas
viru
vigil
et
al
ebola
viru
towner
et
al
rna
virus
recombin
system
power
tool
monitor
viral
infect
real
time
fieg
langloi
fukuyama
et
al
manicassami
et
al
evalu
antivir
nogal
et
al
towner
et
al
identifi
nab
baker
et
al
nogal
et
al
rimmelzwaan
et
al
develop
revers
genet
techniqu
similar
approach
implement
gener
character
replicationcompet
fluorescentexpress
iav
avilov
et
al
baker
et
al
fieg
langloi
fukuyama
et
al
manicassami
et
al
nogal
et
al
nogal
et
al
reuther
et
al
rimmelzwaan
et
al
howev
similar
method
use
gener
recombin
fluorescentexpress
ibv
prepar
manuscript
fulton
et
al
describ
gener
replic
compet
ibv
express
report
gene
viral
polymeras
pa
viral
segment
use
backbon
influenza
byamagata
lineag
fulton
et
al
produc
character
replicationcompet
reporterexpress
virus
backbon
recent
influenza
bvictoria
lineag
use
strategi
similar
one
previous
use
gener
fluoresc
iav
nogal
et
al
achiev
fuse
mcherri
orf
ctermin
end
viral
follow
autoproteolyt
cleavag
site
entir
viral
nep
orf
fig
mediat
cotransl
separ
nep
mechan
term
stopcarri
recod
sharma
et
al
gener
two
function
independ
protein
although
approach
success
use
previous
gener
recombin
fluorescentexpress
iav
manicassami
et
al
nogal
et
al
demonstr
feasibl
use
methodolog
gener
ibv
encod
fluoresc
protein
importantli
ident
modifi
ibvmcherri
ns
segment
confirm
rtpcr
fig
western
blot
fig
furthermor
observ
good
correl
np
posit
cell
mcherri
express
fig
coloc
mcherri
ibvinfect
cell
fig
demonstr
mcherri
express
use
valid
surrog
ibv
infect
importantli
multigrowth
kinet
plaqu
assay
perform
ibvmcherri
show
signific
attenu
compar
wt
counterpart
vitro
fig
vaccin
repres
best
prophylact
option
combat
iav
ibv
infect
pica
pales
simpl
rapid
assay
detect
nab
assist
evalu
humor
immun
respons
induc
tradit
novel
influenza
vaccin
approach
belsh
et
al
et
al
moreov
new
interest
arisen
identif
nab
typespecif
broadli
neutral
properti
due
therapeut
benefit
passiv
immun
peopl
expos
influenza
virus
tan
et
al
nab
iav
ibv
typic
bind
ha
tradit
method
detect
presenc
influenza
nab
includ
hi
vn
assay
advantag
limit
hi
assay
provid
rapid
readout
day
sensit
limit
larg
amount
viru
requir
agglutin
erythrocyt
killian
addit
hi
assay
shown
effect
identif
broadli
neutral
antibodi
et
al
killian
gener
accept
vn
assay
sensit
reliabl
hi
assay
rimmelzwaan
et
al
howev
vn
assay
labori
time
consum
usual
requir
use
secondari
approach
identif
virusinfect
cell
de
jong
et
al
row
et
al
regard
fluorescentexpress
ibv
repres
excel
platform
rapid
sensit
simpl
identif
character
nab
use
fluorescentbas
microneutr
assay
fig
importantli
novel
microneutr
approach
obtain
similar
neutral
titer
obtain
use
convent
microneutr
assay
tabl
moreov
neutral
result
use
iavand
ibvmcherri
similar
obtain
wt
influenza
virus
tabl
although
vaccin
primari
method
control
influenza
antivir
provid
addit
line
defens
particularli
import
control
new
rapidli
spread
antigen
drift
andor
potenti
pandem
viru
garciasastr
oxford
et
al
seibert
et
al
therapeut
option
treatment
prevent
influenza
infect
includ
natarget
zanamivir
oseltamivir
amantadin
rimantadin
inhibitor
jackson
et
al
nguyen
et
al
nguyen
et
al
howev
na
inhibitor
class
antivir
approv
prophylaxi
treatment
patient
infect
ibv
burnham
et
al
although
data
clinic
trial
suggest
oseltamivir
appear
less
effect
ibv
iav
farruke
et
al
addit
emerg
drugresist
variant
increas
problem
control
influenza
infect
nguyen
et
al
seibert
et
al
thu
urgent
medic
need
identif
character
novel
antivir
treatment
influenza
infect
human
task
acceler
develop
rapid
sensit
screen
assay
amen
ht
approach
beyleveld
et
al
identif
compound
inhibit
influenza
typic
reli
use
timeconsum
secondari
assay
assess
viral
infect
thu
altern
approach
facilit
detect
ibv
andor
iav
would
help
identifi
new
antivir
importantli
methodolog
compat
ht
approach
help
simplifi
screen
larg
compound
librari
identifi
hit
ibv
andor
iav
antivir
activ
demonstr
implement
fluorescentexpress
ibv
identifi
character
antivir
drug
evalu
antivir
activ
ribavirin
amantadin
iav
ibv
beigel
bray
nguyen
et
al
nguyen
et
al
nogal
et
al
oxford
et
al
sidwel
et
al
fig
use
novel
fluorescentbas
microneutr
assay
observ
dosedepend
inhibit
iavmcherri
amantadin
ribavirin
ribavirin
dosedepend
inhibitori
effect
ibvmcherri
importantli
viral
inhibit
two
antivir
fluorescentbas
microneutr
assay
similar
obtain
use
wt
iav
ibv
convent
vn
assay
tabl
altogeth
result
demonstr
feasibl
use
replicationcompet
fluorescentexpress
ibv
novel
platform
amen
ht
identif
character
novel
antivir
gfp
introduc
ibv
instead
mcherri
observ
high
level
gfp
express
fig
suggest
feasibl
gener
replicationcompet
ibv
express
other
fluoresc
protein
similar
situat
recent
describ
iav
fukuyama
et
al
manicassami
et
al
howev
like
iav
gfpexpress
ibv
seem
less
stabl
ibvmcherri
data
shown
fukuyama
et
al
manicassami
et
al
nevertheless
abl
gener
stabl
stock
ibvgfp
three
serial
plaqu
purif
mdck
cell
similar
iav
fluoresc
ibv
variant
mcherri
gfp
could
use
address
interest
question
biolog
ibv
includ
frequenc
viral
coinfect
gener
reassort
baker
et
al
moreov
fluorescentexpress
ibv
could
use
combin
previous
describ
fluorescentexpress
iav
fukuyama
et
al
nogal
et
al
bifluorescentbas
microneutr
assay
baker
et
al
rapid
easi
identif
compound
antivir
activ
influenza
virus
likewis
strategi
could
also
use
detect
neutral
antibodi
broadantivir
activ
iav
ibv
character
mcherryexpress
influenza
viru
ibvmcherri
analysi
rna
express
mdck
cell
mock
infect
mock
infect
moi
influenza
wt
mcherryexpress
virus
hpi
total
rna
infect
cell
extract
cdna
synthesi
ns
np
vrna
perform
use
ns
np
vrna
specif
primer
cdna
synthesi
mrna
mcherri
gapdh
perform
use
oligo
dt
specif
primer
pcr
use
amplifi
ns
np
vrna
mcherri
gapdh
mrna
b
analysi
protein
express
mdck
cell
mock
infect
mock
infect
moi
wt
mcherryexpress
ibv
indic
protein
express
level
np
mcherri
evalu
use
protein
specif
antibodi
actin
use
load
control
number
indic
size
molecular
marker
nucleotid
kda
b
dna
protein
product
respect
cd
protein
express
fluoresc
immunofluoresc
mdck
cell
mock
infect
mock
infect
moi
wt
mcherryexpress
ibv
hpi
cell
fix
permeabil
visual
mcherri
express
stain
ibv
np
c
antibodi
dapi
use
nuclear
stain
merg
imag
mcherri
viral
np
c
dapi
illustr
bottom
repres
imag
magnif
includ
scale
bar
fluorescentbas
microneutr
assay
identif
ibv
nab
mdck
cell
infect
moi
mcherryexpress
ibv
ac
iav
df
preincub
serial
dilut
start
dilut
ha
specif
iav
ibv
pab
hpi
viru
neutral
evalu
fluoresc
microscop
quantifi
use
fluoresc
micropl
reader
b
e
percentag
inhibit
calcul
use
sigmoid
dose
respons
curv
c
f
mock
infect
cell
viru
virus
absenc
antibodi
ab
use
intern
control
percent
neutral
normal
infect
absenc
antibodi
data
show
mean
sd
result
determin
triplic
repres
fluoresc
imag
magnif
shown
scale
bar
fluorescentbas
assay
identif
ibv
antivir
mdck
cell
infect
moi
mcherryexpress
ibv
ac
iav
df
incub
serial
dilut
start
concentr
ribavirin
amantadin
intern
control
infect
cell
treat
antivir
drug
hpi
viral
inhibit
evalu
fluoresc
microscop
quantifi
use
fluoresc
micropl
reader
b
e
percentag
inhibit
calcul
use
sigmoid
dose
respons
curv
c
f
mockinfect
cell
viru
use
control
percent
viral
inhibit
normal
infect
absenc
antivir
data
show
mean
sd
result
determin
triplic
repres
fluoresc
microscopi
imag
magnif
shown
scale
bar
b
highest
concentr
use
without
detect
antivir
effect
